A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Trial details
- Registry ID
- NCT02234986
- Drugs studied
- ENMD-2076
TrialRedline tracks 1 clinical trial sponsored by CASI pharmaceuticals, Inc.: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaNCT02234986 | ENMD-2076 | Completed | 2018-06-30Actual |
Names as written in the registry records.